Pasithea Therapeutics (KTTA) Assets Average (2021 - 2026)

Pasithea Therapeutics' Assets Average history runs 6 years deep, the most recent figure standing at $58.3 million for Q1 2026.

• In Q1 2026, Assets Average rose 279.5% year-over-year to $58.3 million; the TTM figure through Mar 2026 stood at $58.3 million (up 279.5% YoY), while the FY2025 annual figure was $38.2 million, up 80.9% from the prior year.
• Assets Average came in at $58.3 million for Q1 2026 at Pasithea Therapeutics, up from $36.9 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $58.3 million in Q1 2026 to a low of $15.3 million in Q3 2025.
• A 5-year average of $33.6 million and a median of $34.4 million in 2023 frame the typical range for Assets Average.
• Across the five-year window, Assets Average tumbled 50.03% in 2024 and surged 279.5% in 2026, its largest moves.
• Pasithea Therapeutics' Assets Average stood at $47.4 million in 2022, then plunged by 40.1% to $28.4 million in 2023, then sank by 38.88% to $17.4 million in 2024, then soared by 112.87% to $36.9 million in 2025, then surged by 57.84% to $58.3 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $58.3 million, $36.9 million, and $15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison